Dydrogesterone came onto the scene in the late 1950s, pushing open doors for synthetic progestins during a time when medicine moved quickly to solve real problems. Before its introduction, doctors relied on natural progesterone, which didn’t play nice with oral dosing because the liver broke it down too fast. Researchers started chasing compounds that mimicked progesterone’s action but survived digestion. Dydrogesterone’s arrival fit the bill: synthesized by Solvay Pharmaceuticals, it provided reliable absorption and activity, helping to shape decades of hormone therapy and reproductive care. The expansion of its use into more countries over the following decades points to its enduring utility and acceptance by health authorities.
Pharmacists and doctors have recognized dydrogesterone under various names, many will recognize it as Duphaston. In tablet form, it stands out because it doesn’t act the same way as other progestogens—dydrogesterone leaves unwanted androgenic effects at the door, and it doesn’t mess with blood fats the way some of its siblings do. The product typically comes as small, scored tablets for patient convenience. Its strength suits most treatment protocols for hormone-related disorders, whether for menstrual irregularities or to support early pregnancy.
Dydrogesterone carries a white crystalline appearance and shows low solubility in water, but enough in some organic solvents, allowing for precise formulation. The molecular formula is C21H28O2, weighing roughly 312 g/mol, reflecting its close structural similarity to natural progesterone, yet the subtle tweaks shape its unique action inside the body. Its melting point sits in the 200°C range, contributing to good shelf stability, which keeps both manufacturers and pharmacists happy. The compound’s UV absorption gives analysts a way to check purity quickly during production.
Bottle labels give the main clues: active ingredient dosage (usually as dydrogesterone 10 mg per tablet), a listing of excipients, and stringent storage recommendations—keep things dry and under 30ºC to stop the tablets from degrading. Packages carry manufacturing and expiration dates so users don’t lose track as supplies rotate in clinics and pharmacies. Pharmacopoeial standards, such as those found in the European Pharmacopoeia, specify acceptable levels of impurities. Products stay traceable through batch numbers and manufacturer details, letting regulators and users track down the source if problems arise. Leaflets inside spell out indications, contraindications, and dosing guidance.
Synthesis starts from steroid precursors found in soybeans or yams, followed by chemical tweaks that rearrange bonds and add a double bond to the progesterone core. Skilled chemists use hydrogenation, selective oxidation, and purification steps to ensure the intended molecular arrangement. Purification usually involves repeated crystallization, sometimes followed by chromatography to hit purity targets set by regulators. The resulting powder gets blended with fillers and pressed into tablets under tight quality control. At every step, analysts confirm the identity and quality of the material before it ever leaves the plant.
To reach dydrogesterone’s activity, researchers modify the parent progesterone molecule by adjusting its double bonds and substituting atoms in just the right position. This careful shaping of the steroid backbone shifts receptor interactions in favor of a gentler, progestin-only effect. Synthetic routes often include Wittig reactions or other alkene-forming strategies, leaving the final product both stable and highly active. Some labs have explored derivatizing dydrogesterone further, but few modifications improve on the combination of oral bioavailability and clean metabolic profile that drew attention in the first place.
Over time, dydrogesterone has picked up synonyms in medical literature and across international markets, including 6-dehydro-9β,10α-progesterone, Degestrone, and its most well-known brand name, Duphaston. Such nomenclature helps clarify references in research papers, clinical guidelines, and regulatory filings. International nonproprietary naming systems ensure healthcare professionals speak the same language about this compound, regardless of region.
Healthcare providers expect tight safety discipline wherever hormone therapy is dispensed, and dydrogesterone is no exception. Workers in tablet production use gloves and dust control to avoid prolonged exposure, although the material itself doesn’t present major risks under normal handling—it isn’t flagged as hazardous in the same way some cytotoxic drugs are. Documented protocols guide every step, from weighing starting materials to final blister packaging. Pharmacists educate patients about potential allergic reactions, rare but real, and review who shouldn’t use it—women with recent blood clots or certain cancers, for instance. Regulators in places like the EU and Japan require periodic review of manufacturing processes to keep patient safety at the center.
Doctors prescribe dydrogesterone for a range of conditions—irregular menstruation, infertility due to luteal phase defects, endometriosis, threatened and recurrent miscarriage, and as part of hormone replacement therapy during menopause. In some countries, it has found a niche in supporting women with a history of pregnancy loss or those undergoing in vitro fertilization. The product’s lack of androgenic or estrogenic activity means side effects like weight gain, acne, or hair changes remain rare, which helps patients stick with treatment. Because it supports the uterine lining without impacting lipid metabolism or blood clotting appreciably, doctors feel more confident using it in women with certain risk profiles.
Academic teams and pharmaceutical developers keep pushing for better data about dydrogesterone’s long-term safety and unique attributes. Clinical trials now explore whether the modern push for “natural” hormone therapy will outshine synthetic options or if dydrogesterone’s stability, safety, and oral availability can compete as a trusted therapy. Research investigating its role in recurrent pregnancy loss and optimal luteal support protocols reflects demand for tailored, evidence-based care. Some studies examine possible immune or vascular effects that don’t show up in short-term use.
Toxicologists ran battery after battery of animal and human studies on dydrogesterone decades ago, looking for signs of mutagenicity, carcinogenicity, or reproductive toxicity. The data showed reassuringly low risks: no clear links to birth defects or major organ toxicity at therapeutic doses, and no evidence of promoting tumors in the way older estrogens did. Monitoring of rare but serious reactions, such as thrombosis, continues in post-marketing surveillance. The safety record stands out among synthetic progestins, especially since it doesn’t convert into other hormones in the liver.
Dydrogesterone continues to attract attention from drug developers looking for even cleaner agents that keep the benefits without adding risks, and doctors hope to narrow down which groups of women stand to gain the most from treatment. With digital health tools expanding, real-world data about drug exposure during pregnancy and long-term follow-up will give more clarity on unresolved safety questions. Rising demand for fertility solutions and tailored menopausal care points to a bright future, provided researchers keep pace with evolving expectations around safety, transparency, and evidence.
Dydrogesterone remains something many women hear about only in a doctor's office—never on the evening news or from friends. Yet for those struggling with painful periods, unexplained infertility, or repeated miscarriages, this prescription drug shapes daily hope. I’ve seen how these challenges eat away at a person’s sense of normalcy. When cycles go off the rails, or pregnancy losses keep piling up, real people feel lost in a maze of blood tests and jargon. Doctors prescribe dydrogesterone because it mimics the effect of progesterone—a hormone key to women’s wellbeing.
Natural progesterone helps prepare the body for pregnancy each month. When levels drop or never rise enough, all sorts of issues pop up. Heavy, irregular periods. Debilitating cramps. Periods that seem to vanish for months. For those trying to conceive, low progesterone turns the odds against them. The uterus lining might not get “sticky” enough, or hold onto an embryo in early pregnancy. Dydrogesterone steps in as a safe option to help restore that hormonal balance and give the body a fair chance at regaining its rhythm.
The history of dydrogesterone stretches back to the 1960s, and over the decades, mountains of clinical research have supported its use. European countries especially favored it because it sparks fewer side effects compared to older synthetic progestins. Where higher risks of blood clots, acne, or weight gain come with some hormones, dydrogesterone tends to have a lighter touch. Clinical trials and published studies have looked at hundreds, even thousands, of women and tracked cycles, pregnancies, and long-term outcomes. Trusted sources like the World Health Organization and peer-reviewed medical journals support its safety and effectiveness.
Doctors use dydrogesterone for specific needs: heavy periods linked to hormonal imbalance, painful menstruation, endometriosis, premenstrual syndrome, and many forms of infertility. It’s also a go-to for helping prevent miscarriages, especially for women who keep facing loss in early pregnancy. Women with certain types of hormone deficiencies during IVF cycles benefit from it, too. These aren’t rare problems—millions struggle with them every year. In these settings, the medicine steps up as a key part of treatment plans for reproductive health.
While dydrogesterone is popular overseas, some countries still don’t approve it or keep supplies tight. This creates worry and stress for people needing treatment continuity, especially if they travel or move across borders. In my small-town pharmacy work, I’ve seen the confusion when someone’s regular prescription suddenly isn’t available. There’s also a general lack of information—patients often turn to forums or social media, hunting for success stories or warnings, because clear, trustworthy answers don’t always show up in public health education.
One way to bridge the information gap is through open, honest conversations with healthcare providers. People deserve to know the strengths and risks of every option, plus what’s backed by science. Medical professionals can do more to translate research into plain language—most folks don’t care about milligrams and molecules, they want to hear about real experiences. Bringing dydrogesterone more into the public conversation also matters. More awareness could push for better access, insurance coverage, and up-to-date guidelines worldwide.
No medicine solves each problem instantly, and not every treatment fits every body. Dydrogesterone offers hope for women facing problems that disrupt their daily life. Trust in this approach remains high among gynecologists, based on a long track record and ongoing research. What works for one person might not work for all—but clear information, strong doctor-patient relationships, and fair access help women take back control over their health journeys.
Dydrogesterone often enters the conversation as a go-to synthetic hormone, mainly prescribed for menstrual disorders, irregular cycles, and certain pregnancy problems. People tend to trust medicines prescribed for long periods, but trust grows shaky the moment side effects show up. Knowing what to expect helps people stay in control of their health, rather than feeling at the mercy of a little white tablet.
No one loves the idea of taking something that could make them feel worse, even temporarily. It isn’t unusual to hear about nausea popping up after starting dydrogesterone. Some women mention feeling like their stomach flips, especially soon after their daily dose. Headaches also find their way into personal accounts — sometimes mild, sometimes strong enough to ruin a good day.
Then comes the story many share: breast tenderness. I’ve heard friends quietly complain about their bra suddenly feeling too tight or an uncomfortable soreness that follows them around. These issues mimic premenstrual syndrome, which causes plenty of people to wonder if the treatment makes something worse before it gets better.
Bloating, mild weight gain, and even dizziness round out the list. For most, these issues fade with time, as the body adjusts. But a few aren’t so lucky, and the frustration can push people back to their doctor looking for answers — or alternatives.
For a smaller number, the issues run deeper. Dydrogesterone, being a synthetic hormone, can rarely cause allergic reactions. Hives, swelling, and breathing issues shouldn’t be brushed aside. Any sign of jaundice — yellowing of skin or eyes — means trouble for the liver and shouldn’t be ignored. The risk sits low, but it hits hard when it happens.
Some studies and post-marketing data signal that mood swings and even depression can tag along with hormone therapy. Most doctors watch for these shifts, yet not everyone feels comfortable sharing mood changes. Honest conversations with health professionals take on new weight when side effects hit your quality of life.
Ignoring side effects brings its own risk. I’ve seen people tough it out, thinking the price of treatment lies only in toughing out discomfort. That approach sometimes leads to missed warning signs or more serious health trouble later. A real understanding — not just reading the list slipped into a pharmacy bag — means knowing which symptoms can wait and which demand urgent action.
Doctors today rely on guidelines, but they also rely on people speaking up. Open discussion can catch a small side effect before it grows or flag a dangerous one before harm sets in. For example, dizziness or migraine-like headaches shouldn’t be shrugged off if they stick around. Keeping a simple notebook for symptoms works better than memory during stressful times.
The fix often depends on how severe the reaction runs. For mild issues, time and lifestyle tweaks, such as switching the time of day for doses or pairing medicine with food, sometimes get things back on track. Whenever I felt unsure, a quick message or visit to my doctor helped clear confusion. Adjusting the dose or exploring other medicines remains an option for persistent trouble.
Education, not fear, leads to better choices. Understanding the risks and watching for the signs keeps treatment safer for everyone using dydrogesterone. Honesty lets both patients and doctors make good calls, staying ahead of the small problems before they grow.
Dydrogesterone shows up in many prescriptions for women facing fertility challenges, period irregularities, or hormonal imbalance. As a synthetic hormone, it takes on a role similar to the body's own progesterone. Doctors trust it in cases from endometriosis to recurrent miscarriages. I remember how a close friend struggled with PCOS, where her physician recommended dydrogesterone alongside dietary changes to help restore her cycles. Seeing her go through this highlighted for me how important it is to not just follow instructions, but also to understand how timing and consistency matter with medication like this.
Doctors usually recommend taking dydrogesterone by mouth, swallowed whole with water. The tablets come with dosage strength clearly marked, often in 10 mg. Some patients take one tablet daily; others follow a more complicated schedule, such as taking it for several days each month. Timing depends on the reason for use: those with menstrual issues might start on a certain day of their cycle, while others may need to continue throughout the cycle or pregnancy. Missing doses reduces the benefit, so keeping pills somewhere visible—by a toothbrush or with morning coffee—helps build a routine.
Hormone therapy often calls for accuracy. Dydrogesterone acts as a messenger in the body's intricate hormonal clock. Skipping, doubling, or spacing out doses can throw off results. Some studies, such as those in medical journals like Fertility and Sterility, found that women who forgot to take their dose at the right time often experienced irregular bleeding or a return of old symptoms. It’s not just about swallowing a tablet; timing regulates the effects. If a dose is missed, most specialists say to take it as soon as remembered, unless it's nearly time for the next one. Trying to double up rarely helps and can cause unwanted side effects.
Every medication brings possible side effects. Nausea, headaches, or mild bloating pop up for some users. Rare symptoms like rash or jaundice deserve quick medical attention. Reading the patient leaflet inside the box or asking a pharmacist reduces worries and catches red flags early. Keeping track of symptoms in a notebook or an app makes it easier to tell if anything changes after starting therapy.
Nobody’s body works exactly like anyone else’s. Doctors tailor dydrogesterone regimens based on age, health status, and specific conditions. If bleeding patterns change, mood feel off, or new symptoms turn up, it pays to bring these up during follow-up appointments. Even a minor change in sleep or stress can influence hormones, so open communication helps doctors adjust therapy before problems grow. My relative’s journey showed me the value of honest feedback—her quick calls about side effects led her care team to tweak her dose, which calmed her symptoms and got things back on track.
A pillbox marked by days, alarms on a mobile phone, or pairing pills with another routine (like teeth-brushing) keeps therapy on track. Joining an online forum or support group connects people with similar experiences, offering reassurance and practical solutions.
People using dydrogesterone shouldn’t be afraid to ask questions or seek support. Relying on a trusted physician and keeping lines of communication open helps keep hormone therapy as simple—and safe—as possible.
Dydrogesterone pops up in clinics and pharmacies for women dealing with infertility, irregular cycles, and threatened miscarriage. Many doctors prescribe it, especially in places like India, Southeast Asia, and parts of Europe. Dydrogesterone works a lot like the hormone progesterone, which keeps pregnancy on track, especially during those uncertain first weeks.
Expecting mothers do not want to gamble. Anything swallowed or injected during pregnancy sets off alarm bells. I remember friends panicking over paracetamol. Over the years, the safety debate around hormones has built up because hormones play such a big role in fetal development. Progesterone helps prepare and maintain the womb, but the synthetic cousins like dydrogesterone tend to raise eyebrows.
According to large studies and years of clinical experience, no clear signs of birth defects or serious harm have emerged with dydrogesterone. The World Health Organization and European Society of Human Reproduction published reviews involving tens of thousands of pregnancies. The big headline? Dydrogesterone didn’t lead to an uptick in congenital malformations or stillbirths.
Doctors in fertility clinics have used dydrogesterone for women with repeated miscarriages. My OB colleagues sometimes give it to women with spotting after years of heartbreak. Studies tracking these women show success stories—higher ongoing pregnancy rates, lower miscarriage rates, and no strong ties to adverse outcomes. Reports in the British Journal of Obstetrics and Gynaecology and Fertility & Sterility paint a reassuring picture.
Still, individual reactions do differ. One woman may breeze through with no side effects. Another might deal with headaches or nausea. Science hasn’t found a direct path from taking dydrogesterone to harming the baby, but doctors do watch out for allergies or rare clotting issues. Self-prescribing, especially from online pharmacies, never ends well—personal health quirks and other medications matter.
Pregnancy already carries uncertainty—plenty of sleepless nights come from googling every odd ache. Anything prescribed during this window deserves scrutiny. Over the past 30 years, other synthetic progestogens have been tied to problems like genital abnormalities in male babies or preterm birth. Dydrogesterone stands out because its chemical structure is closer to natural progesterone, which may explain the lower risk.
It helps to lean on up-to-date research and guidelines. The Royal College of Obstetricians and Gynaecologists gives dydrogesterone the thumbs-up for threatened miscarriage. Most global health regulators haven’t restricted its use, provided it comes through a legitimate prescription.
No drug ever reaches 100 percent safety. Each woman’s health tells a different story—age, history of loss, blood clotting risks, other medicines. Doctors always try to use the lowest effective dose for the shortest proper time. For now, evidence says dydrogesterone helps more than it harms in certain pregnancy risks.
Those facing these choices often feel alone, flipping through forum stories at 2 AM. Open, honest talks with a trusted doctor offer comfort and clarity. Pharmacies and clinics bear real responsibility to provide only legitimate, quality-checked medicines, since counterfeit or fake pills still turn up in some countries. Ongoing research matters too—trials in Africa and Europe still gather pregnancies and outcomes to spot even rare problems.
I've seen hope in the faces of women who finally hold their baby after a rocky start. As medicine evolves, transparency about risks and honest advice go a long way. Dydrogesterone’s safety story looks positive, but everyone deserves a voice in the decision, backed by strong, unbiased science.
Dealing with irregular periods can feel like shooting in the dark. For many women, the promise of better cycle control leads to questions about progesterone-like medicines. Dydrogesterone often comes up during these conversations, usually mentioned in the context of fixing missed or erratic menstrual cycles. This synthetic hormone mimics natural progesterone’s role, which runs the second half of a woman’s cycle, supporting the body’s preparation for a possible pregnancy.
Missed or unpredictable periods often cause more than just a hassle—they can signal deeper issues with hormone balance. Without enough progesterone, the monthly cycle falls apart. Excess estrogen without progesterone’s calming effect can lead to heavy, erratic, or skipped flows. Dydrogesterone steps in as a substitute when the body’s own supply comes up short. It helps stabilize the cycle and cues the lining of the womb to shed, which restores regular bleeding patterns.
Day after day, women share stories about unpredictable cycles. A missed period here, an early one there, and months stuck in limbo. These patterns leave people grappling with anxiety, sometimes worrying about cancer, pregnancy, or menopause. Family doctors often reach for dydrogesterone because its track record stretches back decades. My work in clinics lines up with data: this medicine brings periods back to baseline for many, especially those dealing with conditions like polycystic ovary syndrome (PCOS) or ovulation problems.
Research backs what patients share. In studies, most people taking dydrogesterone for problems like secondary amenorrhea (no periods) or irregular bleeding see a return to regular cycles after a few rounds. A team in Asia reported that over 80% of women regained their periods. The drug usually gets prescribed ten to fourteen days each month, simulating the natural rise and fall of progesterone. Women commonly tolerate it well. Side effects remain mild for most—headache, nausea, maybe a bit of breast tenderness.
Not every woman benefits. Dydrogesterone works best for those with proven progesterone shortfalls, not structural problems like fibroids or stress-induced irregularities. Doctors often order hormone tests or ultrasounds to look for underlying causes before writing a script. Anyone with a history of blood clots, unexplained vaginal bleeding, or certain cancers should mention these before starting treatment.
Drugs like dydrogesterone offer a tool, not a cure-all. Many cases of irregular cycles relate to weight changes, stress, or underlying thyroid trouble. Addressing sleep, nutrition, and mental health can sometimes make as much difference as any pill. For those who do need hormonal support, starting at the right time in the cycle and taking it as prescribed matters. Open conversations between patients and healthcare providers build trust and help tailor a plan that fits each story.
The right answer rarely comes from a single medication. Sometimes a few months of dydrogesterone means a long-term return to regular periods. Other times, it signals a need for further digging: exploring immune, metabolic, or environmental causes. Health teams who listen tend to get better results, blending evidence, empathy, and a willingness to try again if the first approach falls short.
| Names | |
| Preferred IUPAC name | (8S,9S,10R,13S,14S,17R)-10,13-dimethyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl acetate |
| Other names |
6-dehydro-9β,10α-progesterone
6-dehydroretroprogesterone Retrostatin Duphaston |
| Pronunciation | /daɪˌdrɒdʒəˈstɛrəʊn/ |
| Preferred IUPAC name | (8S,9S,10R,13S,14S,17R)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17(17α)-acetone |
| Other names |
6-dehydro-9β,10α-progesterone
Duphaston Dydrogesteronum Dydrogesterona Dydrogesteron Dydrogesteroni |
| Pronunciation | /daɪˌdroʊˈdʒɛstərɒn/ |
| Identifiers | |
| CAS Number | 152-62-5 |
| Beilstein Reference | 136300 |
| ChEBI | CHEBI:4646 |
| ChEMBL | CHEMBL1433 |
| ChemSpider | 71466 |
| DrugBank | DB00378 |
| ECHA InfoCard | 100.057.595 |
| EC Number | EC 3.1.1.37 |
| Gmelin Reference | 6074 |
| KEGG | D00352 |
| MeSH | Dydrogesterone |
| PubChem CID | 3033860 |
| RTECS number | HH8225000 |
| UNII | 18O4710Q4I |
| UN number | UN2811 |
| CAS Number | 152-62-5 |
| 3D model (JSmol) | `3D model (JSmol)` string for **Dydrogesterone**: ``` CCCC1C2CCC3(C=CC(=O)CC3(C)C2CCC1=O)C ``` This is the **SMILES** string, which can be used in JSmol to view the 3D structure. |
| Beilstein Reference | 136152 |
| ChEBI | CHEBI:4645 |
| ChEMBL | CHEMBL1489 |
| ChemSpider | 2296607 |
| DrugBank | DB00378 |
| ECHA InfoCard | 100.040.216 |
| EC Number | EC 3.1.1.1 |
| Gmelin Reference | 1731019 |
| KEGG | D01441 |
| MeSH | D009568 |
| PubChem CID | 3003825 |
| RTECS number | HA4725000 |
| UNII | 77X9W66877 |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C21H28O2 |
| Molar mass | 328.454 g/mol |
| Appearance | White to off-white, crystalline powder |
| Odor | Odorless |
| Density | 1.17 g/cm³ |
| Solubility in water | Practically insoluble in water |
| log P | 2.8 |
| Vapor pressure | 1.25E-08 mmHg at 25°C |
| Acidity (pKa) | 13.85 |
| Basicity (pKb) | 2.90 |
| Magnetic susceptibility (χ) | -9.1e-6 cm³/mol |
| Refractive index (nD) | 1.50 |
| Dipole moment | 3.25 D |
| Chemical formula | C21H28O2 |
| Molar mass | 328.464 g/mol |
| Appearance | White to off-white, odorless, crystalline powder |
| Odor | Odorless |
| Density | 1.27 g/cm³ |
| Solubility in water | Practically insoluble in water |
| log P | 1.98 |
| Basicity (pKb) | 2.70 |
| Magnetic susceptibility (χ) | -9.2e-6 cm³/mol |
| Refractive index (nD) | 1.515 |
| Viscosity | Viscous liquid |
| Dipole moment | 5.47 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 531.8 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -510.2 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -8736.8 kJ/mol |
| Std molar entropy (S⦵298) | 311.1 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -151.5 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -8753 kJ/mol |
| Pharmacology | |
| ATC code | G03DB01 |
| ATC code | G03DB01 |
| Hazards | |
| Main hazards | May cause liver disorders, hypersensitivity reactions, and possible thromboembolic events. |
| GHS labelling | GHS07 |
| Pictograms | Score Line, Oral Use |
| Signal word | No signal word |
| Hazard statements | Dydrogesterone is not classified as a hazardous substance or mixture according to the Globally Harmonized System (GHS). |
| Precautionary statements | Keep out of reach of children. |
| Flash point | 100.7°C |
| Explosive limits | Explosive limits: Non-explosive |
| LD50 (median dose) | LD50 (median dose): >4000 mg/kg (rat, oral) |
| NIOSH | VP8T96T3JW |
| PEL (Permissible) | Not established |
| REL (Recommended) | 40 mg daily |
| IDLH (Immediate danger) | Not Listed |
| Main hazards | May cause liver disorders, hypersensitivity reactions, and potential risk of thromboembolic events. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | lactose, prescription only, oral use |
| Signal word | No signal word |
| Hazard statements | Not a hazardous substance or mixture according to the Globally Harmonized System (GHS) |
| Precautionary statements | Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. Store in a cool, dry place. Use only as directed by a physician. Do not use if you are allergic to dydrogesterone or any of its ingredients. |
| NFPA 704 (fire diamond) | 1-1-0 |
| Flash point | 165.7°C |
| LD50 (median dose) | LD50 (median dose): Mouse oral LD50 4,000 mg/kg |
| NIOSH | NO5010000 |
| PEL (Permissible) | Not established |
| REL (Recommended) | 30 mg daily |
Providing high-quality chemical products and logistics solutions for global trade partners.
